Basf Se Corporation

Anadys Pharmaceuticals, Inc.

Takeda Gmbh

Basf Agro B.v.

Rspr Pharma Ab

Martin Viertelhaus

Fritz Blatter

Tiziana Chiodo

Tobias Seiser

David J Kucera

Joachim Gebhardt

Peter Scott Dragovich

Andreas Hafner

Ulrich Steinbrenner

Chinh Viet Tran

Beate Schmidt

Douglas Eric Murphy

Frank Ruebsam

Andreas Pahl

Gregory Armel

Josef Stadlwieser

Marcus Vossen

Beate Salvador

Michael Rack

Cyrill Zagar

Liliana Parra Rapado

Thomas Maier

Roland Goetz

Tobias Hintermann

Michael Puhl

Martin Szelagiewicz

Sebastian Soergel

Florian Vogt

Dieter Flockerzi

Wen Xu

Birgit Gockel

Gregory Jay Haley

Hermann Tenor

Rolf-Peter Hummel

Christian Hesslinger

Rolf Hellmann

Yuefen Zhou

Torsten Dunkern

Walter Weishaar

Heiko Bernsmann

Lijian Chen

Ragna Hussong

Ewald Benediktus

Matthias Mueller

Olaf Nimz

Dennis Koulelis

Erik J Rueden

Hartwig Schroeder

Laetitia Souillart

Manfred Ehresmann

Anett Perlberg

Karol Horvath

Sebastian Wloch

Peter Oedman

Jacek Malisz

Chung Huan Wong

Tingmin Wang

Ulrika Rosenström

Eric George Klauber

Emiel Jan Kappert

Michael Barros Gross

Daniel Seibert-Ludwig

Anne-Catrin Letzel

Saskia Paehler

Tingman Wang

Manuela Hessmann

Alexander Mann

Hans Christof Holst

Tobias Kanacher

Gregory J Haley

Matthias MÜLLER

The present invention relates to a novel crystalline form of 1-(1,2-dimethylpropyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide recently assigned the common name dimpropyridaz. The invention also relates to the use of the crystalline form B for combating invertebrate pests and to formulations for plant protection which contain the crystalline form B of 1-(1,2-dimethylpropyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide. The crystalline form B according to the present invention can be identified by powder X-ray diffractometry on the basis of its powder X-ray diffraction diagram, hereinafter also termed powder X-ray diffraction pattern or PXRD pattern, of the polymorph form B recorded using Cu—Kα radiation (1.54178 Å) at 25° C. displays the 3 following reflections, quoted as 2θ values: 20.69±0.10°, 24.15±0.10° and 30.52±0.10°. In addition to these 3 reflections, the polymorph B of the present invention may display in such a PXRD pattern one or more, in particular at least 2, often at least 4, in particular at least 6 or at least 8 reflections and especially all of the reflections quoted hereinafter as 2θ values: 7.99±0.10°, 10.07±0.10°, 12.38±0.10°, 15.31±0.10°, 15.97±0.10°, 16.50±0.10°, 18.03±0.10°, 19.29±0.10°, 20.22±0.0.10°, 20.96±0.10°, 23.40±0.10°, 23.70±0.10°, 26.09±0.10°, 27.26±0.10° and 32.91±0.10°.

Crystalline forms of 1-(1,2-dimethylpropyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide

The present invention relates to one crystalline form A of ethyl 2-[2-[2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]phenoxy]acetate, a process for the production of this crystalline form, formulations for plant protection and herbicidal compositions comprising such form A.

Crystalline form of ethyl 2-[2-[2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy]phenoxy]acetate

The present invention relates to a method for obtaining crystalline 2'-fucosyllactose from a 2&#x2032;-FL raw material, which contains 2&#x2032;-FL as a main constituent and at least 0.5% by weight, frequently at least 1% by weight, in particular at least 2% by weight, more particularly at least 5% by weight, and especially at least 8% by weight,based on the total amount of mono-and oligosaccharides in the raw material, of one or more mono- or oligosaccharides different from 2&#x2032;-FL, where the method comprises a)providing a solution of the 2&#x2032;-FL raw material in water, which does not contain more than 10% by weight, preferably not more than 7% by weight, more preferably not more than 5% by weight of organic solvents, based on the total amount of water; b) effecting the crystallization of 2&#x2032;-FL from the solution provided in step a) by inducing conditions of a controlled super saturation in the solution; and c) separating crystalline 2&#x2032;-FL from the mother liquor, and where during controlled supersaturation in step b) not more than 10% by weight, preferably not more than 7% by weight, more preferably not more than 5% by weight of organic solvents are present, based on the total amount of water present during step b).

Method for obtaining crystalline 2'-fucosyllactose

The present invention relates to crystalline forms of ethyl[3-[2-chloro-4-fluoro-5-(1-methyl-6-trifluoromethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-3-yl)phenoxy]-2-pyridyloxy]acetate (CAS 353292-31-6), herein after also referred to as 'compound of formula (I)'. The invention also relates to a process for the production of these crystalline forms, formulations for plant protection and herbicidal compositions which contain one of these crystalline forms.

Crystalline forms of ethyl[3-[2-chloro-4-fluoro-5-(1-methyl-6-trifluoromethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-3-yl)phenoxy]-2-pyridyloxy]acetate

The present invention relates to crystalline forms of ethyl 2-[[3-[[3-chloro-5-fluoro-6-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]-2-pyridyl]oxy]-2-pyridyl]oxy]acetate, herein after also referred to as 'compound of formula (I)'. The invention also relates to a process for the production of these crystalline forms, formulations for plant protection and herbicidal compositions which contain one of these crystalline forms.

Crystalline forms of ethyl 2-[[3-[[3- chloro-5-fluoro-6-[3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]-2-pyridyl]oxy] acetate

The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and solvents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.

Multi-component crystals of vismodegib and selected co-crystal formers or solvents

The present invention relates to a process for the preparation of oxirane compounds of formula II from keto compounds III using dimethyl sulfide (CH)S and dimethylsulfate (CH)SO, forming the reagent IV, trimethylsulfonium methylsulfate [(CH)SCHSO], in aqueous solution in the presence of potassium hydroxide (KOH).

Process for the preparation of substituted oxiranes and triazoles

Combinations of (3&#x3b2;)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acid are useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.

Solid form of abiraterone acetate

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase and are useful for treating or preventing idiopathic pulmonary lung fibrosis.

Methylpyrrolopyrimidinecarboxamides

There is provided a hemihydrate form of the sodium salt of pemirolast.

Crystalline form of pemirolast

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I  

5,6-D hydro-1H-pyridin-2-one compounds

The invention is directed to a 5,6-dihydro-1H-pyridin-2-one compound selected from: 

[object Object]

The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2'-O-acetyl-3&#x2032;-deoxy-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions such as viral infections, tumors, and cancer.  Also disclosed is a method of preparing the p-toluene sulfonic acid salt of 5-amino-3-(2&#x2032;-O-acetyl-3&#x2032;-deoxy-&#x3b2;-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and methods for producing furanose compounds which are useful intermediates in the preparation of pharmaceutical compounds such as p-toluene sulfonic acid salt of 5-amino-3-(2&#x2032;-O-acetyl-3&#x2032;-deoxy-&#x3b2;-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.

P-toluene sulfonic acid salt of 5-amino-3-(2'-O-acetyl-3&#x2032;-deoxy-&#x3b2;-D-ribofuranosyl)-3H-thiazole[4,5-d]pyrimidine-2-one and methods for preparation

Growing community of inventors

Mannheim, Germany

Martin Viertelhaus